These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 34932102)

  • 1. A Randomized Phase 1/2 Study of a Respiratory Syncytial Virus Prefusion F Vaccine.
    Walsh EE; Falsey AR; Scott DA; Gurtman A; Zareba AM; Jansen KU; Gruber WC; Dormitzer PR; Swanson KA; Radley D; Gomme E; Cooper D; Schmoele-Thoma B
    J Infect Dis; 2022 Apr; 225(8):1357-1366. PubMed ID: 34932102
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Respiratory Syncytial Virus Prefusion F Vaccination: Antibody Persistence and Revaccination.
    Walsh EE; Falsey AR; Zareba AM; Jiang Q; Gurtman A; Radley D; Gomme E; Cooper D; Jansen KU; Gruber WC; Swanson KA; Schmoele-Thoma B
    J Infect Dis; 2024 Oct; 230(4):e905-e916. PubMed ID: 38606958
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase 1/2 Randomized Study of the Immunogenicity, Safety, and Tolerability of a Respiratory Syncytial Virus Prefusion F Vaccine in Adults With Concomitant Inactivated Influenza Vaccine.
    Falsey AR; Walsh EE; Scott DA; Gurtman A; Zareba A; Jansen KU; Gruber WC; Dormitzer PR; Swanson KA; Jiang Q; Gomme E; Cooper D; Schmoele-Thoma B
    J Infect Dis; 2022 Jun; 225(12):2056-2066. PubMed ID: 34931667
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Equivalent immunogenicity across three RSVpreF vaccine lots in healthy adults 18-49 years of age: Results of a randomized phase 3 study.
    Baker J; Aliabadi N; Munjal I; Jiang Q; Feng Y; Brock LG; Cooper D; Anderson AS; Swanson KA; Gruber WC; Gurtman A
    Vaccine; 2024 May; 42(13):3172-3179. PubMed ID: 38616438
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prefusion F Protein-Based Respiratory Syncytial Virus Immunization in Pregnancy.
    Simões EAF; Center KJ; Tita ATN; Swanson KA; Radley D; Houghton J; McGrory SB; Gomme E; Anderson M; Roberts JP; Scott DA; Jansen KU; Gruber WC; Dormitzer PR; Gurtman AC
    N Engl J Med; 2022 Apr; 386(17):1615-1626. PubMed ID: 35476650
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Phase 1/2 Study of a Respiratory Syncytial Virus Prefusion F Vaccine With and Without Adjuvant in Healthy Older Adults.
    Baber J; Arya M; Moodley Y; Jaques A; Jiang Q; Swanson KA; Cooper D; Maddur MS; Loschko J; Gurtman A; Jansen KU; Gruber WC; Dormitzer PR; Schmoele-Thoma B
    J Infect Dis; 2022 Dec; 226(12):2054-2063. PubMed ID: 35543281
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity and Safety of 3 Formulations of a Respiratory Syncytial Virus Candidate Vaccine in Nonpregnant Women: A Phase 2, Randomized Trial.
    Schwarz TF; McPhee RA; Launay O; Leroux-Roels G; Talli J; Picciolato M; Gao F; Cai R; Nguyen TL; Dieussaert I; Miller JM; Schmidt AC
    J Infect Dis; 2019 Oct; 220(11):1816-1825. PubMed ID: 31418022
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and Immunogenicity of Bivalent RSVpreF Vaccine Coadministered With Seasonal Inactivated Influenza Vaccine in Older Adults.
    Athan E; Baber J; Quan K; Scott RJ; Jaques A; Jiang Q; Li W; Cooper D; Cutler MW; Kalinina EV; Anderson AS; Swanson KA; Gruber WC; Gurtman A; Schmoele-Thoma B;
    Clin Infect Dis; 2024 May; 78(5):1360-1368. PubMed ID: 37992000
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of bivalent RSVpreF maternal vaccination to prevent RSV illness in Japanese infants: Subset analysis from the pivotal randomized phase 3 MATISSE trial.
    Otsuki T; Akada S; Anami A; Kosaka K; Munjal I; Baber J; Shoji Y; Aizawa M; Swanson KA; Gurtman A
    Vaccine; 2024 Sep; 42(22):126041. PubMed ID: 38853036
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and Immunogenicity of an Investigational Respiratory Syncytial Virus Vaccine (RSVPreF3) in Mothers and Their Infants: A Phase 2 Randomized Trial.
    Bebia Z; Reyes O; Jeanfreau R; Kantele A; De Leon RG; Sánchez MG; Banooni P; Gardener GJ; Rasero JLB; Pardilla MBE; Langley JM; Di Leo CM; Botelho-Nevers E; Buttery J; Laurichesse H; Madhi SA; García AM; Stanley T; Barjat T; Griffith R; Castrejón-Alba MM; de Heusch M; Dieussaert I; Hercor M; Lese P; Qian H; Tullio AN; Henry O
    J Infect Dis; 2023 Aug; 228(3):299-310. PubMed ID: 36722147
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and Immunogenicity of a Respiratory Syncytial Virus Prefusion F Vaccine When Coadministered With a Tetanus, Diphtheria, and Acellular Pertussis Vaccine.
    Peterson JT; Zareba AM; Fitz-Patrick D; Essink BJ; Scott DA; Swanson KA; Chelani D; Radley D; Cooper D; Jansen KU; Dormitzer PR; Gruber WC; Gurtman A
    J Infect Dis; 2022 Jun; 225(12):2077-2086. PubMed ID: 34637519
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and Immunogenicity of a Revaccination With a Respiratory Syncytial Virus Prefusion F Vaccine in Older Adults: A Phase 2b Study.
    Leroux-Roels I; Van Ranst M; Vandermeulen C; Abeele CV; De Schrevel N; Salaun B; Verheust C; David MP; Kotb S; Hulstrøm V
    J Infect Dis; 2024 Feb; 229(2):355-366. PubMed ID: 37699064
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase 1 Safety and Immunogenicity Study of a Respiratory Syncytial Virus Vaccine With an Adenovirus 26 Vector Encoding Prefusion F (Ad26.RSV.preF) in Adults Aged ≥60 Years.
    Williams K; Bastian AR; Feldman RA; Omoruyi E; de Paepe E; Hendriks J; van Zeeburg H; Godeaux O; Langedijk JPM; Schuitemaker H; Sadoff J; Callendret B
    J Infect Dis; 2020 Aug; 222(6):979-988. PubMed ID: 32320465
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity and Safety Following 1 Dose of AS01E-Adjuvanted Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults: A Phase 3 Trial.
    Schwarz TF; Hwang SJ; Ylisastigui P; Liu CS; Takazawa K; Yono M; Ervin JE; Andrews CP; Fogarty C; Eckermann T; Collete D; de Heusch M; De Schrevel N; Salaun B; Lambert A; Maréchal C; Olivier A; Nakanwagi P; Lievens M; Hulstrøm V
    J Infect Dis; 2024 Jul; 230(1):e102-e110. PubMed ID: 39052726
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alternative Virus-Like Particle-Associated Prefusion F Proteins as Maternal Vaccines for Respiratory Syncytial Virus.
    Blanco JCG; Fernando LR; Zhang W; Kamali A; Boukhvalova MS; McGinnes-Cullen L; Morrison TG
    J Virol; 2019 Dec; 93(23):. PubMed ID: 31511382
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and immunogenicity of a respiratory syncytial virus fusion glycoprotein F subunit vaccine in healthy adults: Results of a phase 1, randomized, observer-blind, controlled, dosage-escalation study.
    Leroux-Roels G; De Boever F; Maes C; Nguyen TL; Baker S; Gonzalez Lopez A
    Vaccine; 2019 May; 37(20):2694-2703. PubMed ID: 30987852
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase 1, randomized, placebo-controlled study to evaluate the safety and immunogenicity of an mRNA-based RSV prefusion F protein vaccine in healthy younger and older adults.
    Aliprantis AO; Shaw CA; Griffin P; Farinola N; Railkar RA; Cao X; Liu W; Sachs JR; Swenson CJ; Lee H; Cox KS; Spellman DS; Winstead CJ; Smolenov I; Lai E; Zaks T; Espeseth AS; Panther L
    Hum Vaccin Immunother; 2021 May; 17(5):1248-1261. PubMed ID: 33121346
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and Immunogenicity of 3 Formulations of an Investigational Respiratory Syncytial Virus Vaccine in Nonpregnant Women: Results From 2 Phase 2 Trials.
    Beran J; Lickliter JD; Schwarz TF; Johnson C; Chu L; Domachowske JB; Van Damme P; Withanage K; Fissette LA; David MP; Maleux K; Schmidt AC; Picciolato M; Dieussaert I
    J Infect Dis; 2018 Apr; 217(10):1616-1625. PubMed ID: 29401325
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Parainfluenza Virus Vector Expressing the Respiratory Syncytial Virus (RSV) Prefusion F Protein Is More Effective than RSV for Boosting a Primary Immunization with RSV.
    Liang B; Matsuoka Y; Le Nouën C; Liu X; Herbert R; Swerczek J; Santos C; Paneru M; Collins PL; Buchholz UJ; Munir S
    J Virol; 2020 Dec; 95(2):. PubMed ID: 33115876
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and Immunogenicity of a Respiratory Syncytial Virus Prefusion F (RSVPreF3) Candidate Vaccine in Older Adults: Phase 1/2 Randomized Clinical Trial.
    Leroux-Roels I; Davis MG; Steenackers K; Essink B; Vandermeulen C; Fogarty C; Andrews CP; Kerwin E; David MP; Fissette L; Vanden Abeele C; Collete D; de Heusch M; Salaun B; De Schrevel N; Koch J; Verheust C; Dezutter N; Struyf F; Mesaros N; Tica J; Hulstrøm V
    J Infect Dis; 2023 Mar; 227(6):761-772. PubMed ID: 35904987
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.